MAXIMIZING ONCOLOGY RESEARCH WITH BUILT-IN KRAS ASSAY COMPANIES AND RAS ASSAYS

during the speedily evolving area of oncology exploration, correct and successful mutation screening is critical for building focused therapies. The KRAS companies Platform performs a pivotal part Within this landscape by supplying thorough remedies for KRAS mutation profiling and analysis. KRAS mutations, present in close to 95% of RAS-similar onc